ARTICLE | Clinical News
AZD3759: Preliminary Phase I data
June 1, 2015 7:00 AM UTC
Preliminary data from 2 evaluable patients with EGFR mutation-positive NSCLC with brain metastasis in an open-label, dose-escalation, international Phase I trial showed that twice-daily 50 and 100 mg ...